Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus platinum-etoposide vs placebo for extensive-stage small cell lung cancer
CTR20213232Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in small cell lung cancer (SCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2022; status: completed.
02
Drugs
toripalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20213232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213232.